Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Deals Digital

Meinian Onehealth Collaborates with Huawei Cloud and Runda Medical on AI Health Robot

Fineline Cube Jan 19, 2024

Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a strategic partnership with...

Company Deals

Sinovac Biotech Ltd Dismisses UK Private Equity’s Nominal Share Acquisition Offer

Fineline Cube Jan 19, 2024

Sinovac Biotech Ltd (NASDAQ: SVA) has released a statement declaring that its board of directors...

Company Drug

Beijing Aosaikang Initiates Phase III Trial for Advanced Gastric Cancer Treatment

Fineline Cube Jan 18, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has registered a Phase...

Company Deals R&D

Zhejiang Dian Diagnostics Partners with Gulf Medical University for Middle East Expansion

Fineline Cube Jan 18, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a Chinese diagnostics company, has entered into a...

Company Drug

FDA Approves Casgevy, the First CRISPR-Based Gene Editing Therapy for β-Thalassemia

Fineline Cube Jan 18, 2024

Casgevy (exagamglogene autotemcel), the pioneering gene editing therapy based on CRISPR technology, has received approval...

R&D

Sun Yat-sen University Researchers Develop AI Model for Early Ovarian Cancer Detection

Fineline Cube Jan 18, 2024

Researchers at Guangzhou’s Sun Yat-sen University Cancer Center have made a significant breakthrough with the...

Company Drug

Shanghai-Based NK CellTech Earns FDA IND Clearance for Non-Genetically Modified NK Cell Therapy

Fineline Cube Jan 18, 2024

NK CellTech, a Shanghai-based developer of NK cell therapies, has announced that it has received...

Policy / Regulatory

Hainan Province Unveils Measures to Support Innovative Drugs and Medical Devices Development

Fineline Cube Jan 18, 2024

Hainan provincial bureaus, including the Healthcare Security Administration (HSA), Healthcare Commission, and Medical Products Administration,...

Legal / IP Policy / Regulatory

Shanghai Medical Products Administration Issues Trial Measures for Pharmaceutical Quality and Safety Personnel

Fineline Cube Jan 18, 2024

The Shanghai medical products administration has released the “Measures for the Management of Key Quality...

Company Legal / IP

USPTO Invalidates Key Seagen-Held Patent in ADC Conjugation Dispute with Daiichi Sankyo

Fineline Cube Jan 18, 2024

In a surprising turn of events in the ongoing intellectual property dispute, the US Patent...

Company

Bayer Unveils New Operating Model to Drive Profitable Growth Amid Challenges

Fineline Cube Jan 18, 2024

Facing a challenging business landscape, Germany’s Bayer (ETR: BAYN) has announced a new operating model...

Company Drug

Eisai and Medivir’s Combo Therapy Advances in Liver Cancer with Positive Trial Results

Fineline Cube Jan 18, 2024

Japanese pharmaceutical company Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib), combined with Swedish partner Medivir’s...

Legal / IP Policy / Regulatory

Shanghai Enhances Biomedicine IP Protection with New Procurement-Linked Measures

Fineline Cube Jan 18, 2024

The Shanghai Intellectual Property Administration (SIPA) has issued a notification highlighting the city’s intensified efforts...

Company Drug

Hansoh Pharmaceutical Advances Schizophrenia Treatment with HS-10509 Clinical Trial Approval

Fineline Cube Jan 18, 2024

Hansoh Pharmaceutical (HKG: 3692) has announced that it has received approval to commence clinical trials...

Company Drug

Sino Biopharmaceutical Receives NMPA Approval for Generic Revolade Equivalent

Fineline Cube Jan 18, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a major player in the Chinese pharmaceutical industry, announced that...

Company Drug

Luye Pharma’s Biosimilar Bevacizumab Gets GMP Certification in Brazil

Fineline Cube Jan 18, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...

Company Drug

Regenxbio’s One-Time Gene Therapy for Wet AMD Shows Promise in Phase II Study

Fineline Cube Jan 17, 2024

Gene therapy specialist Regenxbio (NASDAQ: RGNX) has announced preliminary results from a Phase II study...

Company Drug

Takeda’s Hyqvia Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 17, 2024

Japanese pharmaceutical company Takeda (TYO: 4502) has received an indication extension approval from the US...

Policy / Regulatory

China Regulators Chart Steady Path for ‘Huiminbao’ Medical Insurance Schemes

Fineline Cube Jan 17, 2024

The China Banking and Insurance Regulatory Commission (CBIRC) and National Healthcare Security Administration (NHSA) have...

Company Drug

Qilu Pharmaceutical’s Iruplinalkib Gains Additional Indication Approval in China for ALK-Positive NSCLC

Fineline Cube Jan 17, 2024

The National Medical Products Administration (NMPA) website has indicated that Qilu Pharmaceutical’s Category 1 drug,...

Posts pagination

1 … 456 457 458 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.